| 摘要 |
Disclosed are azaindazole compounds of Formula (I):;
or a pharmaceutically acceptable salt thereof, wherein: X is O and Y is N; or X is S and Y is CH; Z is CR2 or N; Q is a heteroaryl; and R1 is defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 assoC1ated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds. |
| 主权项 |
1. A compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: X is S and Y is CH; Z is CR2 or N: Q is: R1 is: (i) halo, C1 -4fluoroalkyl, C1-6alkoxy, C1-4fluoroalkoxy, —S(C1-4fluoroalkyl), —O(C1-4alkylenyl)O(C1-3alkyl), —O(CH2)1-4N(C1-3alkyl)2, —O(C3-6alkynyl), or —O(methylpiperidinyl); (ii) phenyl substituted with zero to 2 substituents independently selected from F, Cl, —CF3, and/or —OCH3; (iii) C3-6cycloalkyl, morpholinyl, thiazolyl, pyridinyl, pyridazinyl, or pyrazinyl; or (iv) —O(CH2)1-4Rx wherein Rx is imidazolyl, thiazolyl, phenyl, fluorophenyl, chlorophenyl, methoxyphenyl, naphthalenyl, or pyrazinyl; R2 is H or —NHS(O)2(C1-4alkyl); and R3 is: (i) F, Cl, C1-4alkyl, C1-4alkoxy, or C1-4fluoroalkoxy; (ii) C3-6cyclopropyl, morpholinyl, pyrazolyl, imidazolyl, or triazolyl; (iii) —O(CH2)1-4Ry wherein Ry is phenyl, morpholinyl, or pyridazinyl; (iv) pyrrolidinyl substituted with zero to 2 substituents independently selected from —CH3 and/or —OH; or (v) —NH2, —NH(C1-4alkyl), —NH(C2-3fluoroalkyl), or —NH(C3-6cycloalkyl). |
